Topic

Virginia

A collection of 404 issues

Renewing iLink® Corneal Cross-Linking Coverage with UnitedHealthcare in Virginia: Timeline, Documentation & Appeals Guide

Quick Answer: Renewing Your iLink® Coverage UnitedHealthcare requires annual prior authorization renewal for iLink® corneal cross-linking. Start the renewal process 4-6 weeks before your current authorization expires. You'll need updated corneal topography showing continued progression, a medical necessity letter from your ophthalmologist, and evidence of treatment response. Submit
6 min read

How to Get Daybue (Trofinetide) Covered by Cigna in Virginia: Complete PA Guide with Forms and Appeal Timeline

Answer Box: Getting Daybue (Trofinetide) Covered by Cigna in Virginia Cigna requires prior authorization for Daybue (trofinetide) through their specialty pharmacy Accredo. Key requirements: confirmed Rett syndrome diagnosis with MECP2 genetic testing, patient age ≥2 years, and specialist prescriber (neurologist/geneticist). If denied, you have 180 days to file an
5 min read

Aetna (CVS Health)'s Coverage Criteria for Pemazyre (pemigatinib) in Virginia: What Counts as "Medically Necessary"?

Quick Answer: Getting Pemazyre (pemigatinib) Covered by Aetna (CVS Health) in Virginia Pemazyre requires prior authorization from Aetna (CVS Health) and is typically non-formulary, requiring a formulary exception. The fastest path to approval: (1) Submit complete documentation including positive FGFR2/FGFR1 molecular test results, prior therapy history, and baseline ophthalmologic
6 min read

Renewing Vimizim (Elosulfase Alfa) Coverage with Humana in Virginia: Complete Guide to Timelines, Documentation, and Appeals

Answer Box: Fast Track to Vimizim Renewal Humana requires prior authorization renewal for Vimizim (elosulfase alfa) in Virginia with specific documentation proving ongoing medical necessity. Start your renewal 2-4 weeks before expiration to avoid treatment gaps. Submit updated clinical assessments (6-minute walk test, pulmonary function), chart notes showing therapeutic response,
6 min read